Five-year outcomes of patients supported with HeartMate 3: a single-centre experience
Jazyk angličtina Země Německo Médium print
Typ dokumentu časopisecké články
PubMed
33585913
DOI
10.1093/ejcts/ezab018
PII: 6135342
Knihovny.cz E-zdroje
- Klíčová slova
- Heart failure, HeartMate 3, Left ventricular assist device, Mechanical circulatory support,
- MeSH
- kvalita života MeSH
- lidé MeSH
- podpůrné srdeční systémy * MeSH
- prospektivní studie MeSH
- srdeční selhání * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: The HeartMate 3 left ventricular assist device was first implanted in 2014 and received the Conformité Européenne mark in 2015. Since then, several trials demonstrated its high haemocompatibility associated with good survival and low adverse events rates. Herein, we report our institutional experience with patients supported with HeartMate 3 for 5 years. METHODS: This prospective cohort study included patients receiving a HeartMate 3 implantation in 2014 as part of the HeartMate 3 Conformité Européenne Mark clinical trial. Patients had follow-up visits every 3 months while on left ventricular assist device support, and all patients completed the 5-year follow-up. The primary end point was survival at 5 years. Secondary end points included adverse events, health status and quality of life. RESULTS: Eight patients (men: 75%) aged 59 years (min-max: 52-66 years) were enrolled. At 5 years, survival was 100%. Patients remained on support for a median time of 1825 days (min-max: 101-1825 days); 2 patients successfully received cardiac transplants. No right heart failure, haemolysis, pump thrombosis, pump malfunction or neurological events occurred in any patients. A driveline infection was observed in 6 patients (0.25 events/patient-year). Compared to baseline, a significant improvement in quality of life and in New York Heart Association functional class was noted after the implant and for the whole follow-up time. A slight decline in kidney function and in the 6-min walk test results occurred after 3 years. CONCLUSIONS: This study reports the longest single-centre follow-up of the HeartMate 3, showing excellent haemocompatibility over time with high survival and low complication rates at 5 years.
Clinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center Bad Oeynhausen Germany
Department of Cardiology and Angiology Hannover Medical School Hannover Germany
Department of Cardiothoracic and Vascular Surgery German Heart Center Berlin Berlin Germany
Division of Cardiac Surgery Department of Surgery Medical University Vienna Vienna Austria
National Research Cardiac Surgery Center Nur Sultan Kazakhstan
University Department of Cardiac Surgery Heart Center Leipzig Leipzig Germany
Citace poskytuje Crossref.org